Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Biogen - What They Never Told You

FDA Approves Weekly At-Home Injection of Leqembi for Alzheimer's Patients Starting Treatment

FDA approved LEQEMBI IQLIK on July 13, 2026, a weekly at-home autoinjector for early Alzheimer's patients. Here's what it means and what patients should know.

Medical Daily

The Alzheimer's Protein Long Blamed for Dementia May Actually Be Critical for Memory, Scientists Find

Flinders University study in Nature Communications finds tau is essential for long-term memory formation — not just Alzheimer's pathology. What this means for drug development.

Medical Daily

New experimental drug shows promise in slowing early Alzheimer’s

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta…

The Economic Times

Biogen's Q2 2026 Earnings: What to Expect

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Barchart

How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

MarketBeat

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

MarketBeat

Are Wall Street Analysts Bullish on Biogen Stock?

Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference. Speaking

MarketBeat

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s

MarketBeat

Genome sequencing is rewriting the history of disease outbreaks – but without social context, it can tell only part of the story

Fingerprinting transformed police investigations by making it possible to place a suspect at a crime scene with physical evidence. Similarly, genome sequencing has changed how disease detectives study outbreaks by allowing them to read a pathogen’s genes as a biological record of where it came from and how it spread.

The Conversation

FDA Extends Review of Eisai, Biogen Alzheimer's Drug

The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Biogen Earnings Preview: What to Expect

Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s bottom-line figure.

Barchart

Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini S&P futures (ESM26 ) rose +2.88%, and June E-mini Nasdaq futures...

Barchart

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

Barchart

Stocks Climb on Hopes for an End to Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. June E-mini S&P futures (ESM26 ) are up +1.10%, and June E-mini Nasdaq futures...

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

'Conservatives' want to tax university research. It would kill the goose that lays America's golden eggs

Proposals to levy royalties on university patent licensing threaten to gut the tech-transfer system that spawned Google, Biogen and nearly 20,000 startups.

Barchart

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

MarketBeat

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

Barchart

What to Expect From Biogen's Next Quarterly Earnings Report

Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

International Business Times UK

NHS Refuses to Fund Life-Saving Motor Neurone Disease Medication Despite Free Supply From Drugmaker

MND patients in the UK denied access to lifesaving drug tofersen, despite Biogen supplying it free, due to NHS covering administration costs.

Barchart

MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too?

MSTR was being eyed for possible Nasdaq-100 removal, but when the index reconstitutes next week, it will get to stay. Other companies, including Biogen and Lululemon, will be removed.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.